(Q51450937)

5 April 2018

title

Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer. (English)

1 reference

5 April 2018

1 reference

Adam Rzechonek

1

1 reference

5 April 2018

Aleksandra Kaminska

2

1 reference

5 April 2018

Piotr Mamczur

3

1 reference

5 April 2018

Arkadiusz Drapiewski

4

1 reference

5 April 2018

Władysław Budzynski

5

1 reference

5 April 2018

language of work or name

English

0 references

publication date

29 September 2016

1 reference

5 April 2018

Advances in Experimental Medicine and Biology

published in

1 reference

5 April 2018

volume

955

1 reference

5 April 2018

page(s)

51-57

1 reference

5 April 2018

Pyruvate kinase M2 is a phosphotyrosine-binding protein

cites work

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Diagnostic value of fecal tumor M2-pyruvate kinase for CRC screening: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Targeting pyruvate kinase M2 contributes to radiosensitivity of non-small cell lung cancer cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

The 7th lung cancer TNM classification and staging system: Review of the changes and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Revisions in the International System for Staging Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

Tumor M2-Pyruvate Kinase as Tumor Marker in Exocrine Pancreatic Cancer A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F5584_2016_92

21 January 2018

Identifiers

DOI

10.1007/5584_2016_92

1 reference

5 April 2018

1 reference

5 April 2018